Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Flurazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.48 |
| ▸ | GABRA5 known ✓ | P31644 | 4/20 | 0.48 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 0.48 |
| ▸ | GABRA2 known ✓ | P47869 | 4/20 | 0.48 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.48 |
| ▸ | GABRG2 known ✓ | P18507 | 3/20 | 0.48 |
| ▸ | GABRB3 known ✓ | P28472 | 3/20 | 0.48 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.48 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.48 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.48 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.48 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | GHSR | Q92847 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flurazepam SCHEMBL29792 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL29368156 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL29378257 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL30690402 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL18396062 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL5499515 | 1.00 | OPRK1 (0.98) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL29793 | 0.99 | OPRK1 (1.00) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL10587083 | 0.99 | OPRK1 (1.00) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL29565153 | 0.99 | OPRK1 (1.00) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL1650117 | 0.97 | OPRK1 (0.96) | OPRK1DRD3KCNH2GHSRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2973 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316057-A1 | PULSATILE RELEASE CAFFEINE FORMULATION | GALVENTA AG (TR) | 2024-09-26 | — | — | US | claimed |
| US-20230381195-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2023-11-30 | — | — | US | claimed |
| EP-4277607-A1 | PULSATILE RELEASE CAFFEINE FORMULATION | Galventa AG (CH) | 2023-11-22 | — | — | EP | claimed |
| WO-2022152863-A1 | PULSATILE RELEASE CAFFEINE FORMULATION | GALVENTA GMBH (CH) | 2022-07-21 | — | — | WO | claimed |
| US-20210106592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2021-04-15 | — | — | US | claimed |
| WO-2020030991-A1 | DOSAGE FORM FOR INSERTION INTO THE MOUTH | NAL PHARMACEUTICAL GROUP LIMITED (CN) | 2020-02-13 | — | — | WO | claimed |
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| CN-107441496-A | Oral dosage form | 安能泰制药有限公司 | 2017-12-08 | — | — | CN | claimed |
| US-9579295-B2 | Dosage form for insertion into the mouth | NAL PHARMACEUTICAL GROUP LIMITED (HK) | 2017-02-28 | — | — | US | claimed |
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| EP-1095136-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | Messing, Robert O. (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000018447-A2 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-2000001805-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | claimed |
| WO-1999051209-A1 | PRESS COATED, PULSATILE DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |